Fmr LLC Raises Stock Position in OmniAb, Inc. (NASDAQ:OABI)

Fmr LLC raised its holdings in OmniAb, Inc. (NASDAQ:OABI) by 10.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 138,813 shares of the company’s stock after acquiring an additional 13,324 shares during the period. Fmr LLC’s holdings in OmniAb were worth $587,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OABI. Atria Investments Inc acquired a new position in shares of OmniAb in the 3rd quarter valued at $148,000. Isthmus Partners LLC grew its holdings in OmniAb by 37.2% in the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock valued at $1,981,000 after purchasing an additional 143,387 shares during the period. Rice Hall James & Associates LLC increased its position in shares of OmniAb by 6.4% in the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after buying an additional 163,038 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of OmniAb in the second quarter valued at approximately $147,000. Finally, Sei Investments Co. raised its stake in shares of OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after buying an additional 2,888 shares during the period. 72.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on OABI. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Stock Performance

Shares of OABI opened at $3.56 on Thursday. The stock has a market capitalization of $502.73 million, a price-to-earnings ratio of -5.74 and a beta of -0.14. OmniAb, Inc. has a one year low of $3.54 and a one year high of $6.72. The stock has a 50 day moving average price of $4.02 and a 200 day moving average price of $4.18.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.